NEVADANANO
18.5.2021 16:51:13 CEST | Business Wire | Press release
NevadaNano, the world’s leading innovator in gas detection sensor technology, today announced it signed three prominent distributors as it continues its expansion throughout Europe. The companies will provide local support and sales to NevadaNano’s growing customer base for its ground-breaking Molecular Property Spectrometer™ (MPS™) flammable gas sensors.
“The addition of these three market-leading companies underscores the demand for an innovative sensor like the MPS, one that redefines the standard after nearly 40 years,” said Gary Collins, General Manager, EMEA for NevadaNano. “We are confident that our novel technology and their deep experience of these companies will help their customers develop leading-edge products with highly accurate and reliable gas detection technology.”
- Maritex Company , based in Gdynia, Poland, is one of the largest, fast-developing wholesalers of electronic equipment on the Polish market. The company supports customers in Poland, Romania, and Sweden.
- Gas Sensor RU is a leading supplier of gas sensing solutions across Russia, Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, and Ukraine. The company focuses on securing the environment and people’s safety in the fast-growing industry and world.
- GVZ Components , based in Italy, is a key supplier across Europe in the sensors' market with more than 40 years of experience supplying leading companies in a wide range of applications: from automotive to HVAC-R, from medical to industrial, from military to aerospace.
NevadaNano offers a range of unique gas detection sensors for flammables, refrigerants (A1, A2L and A3’s) and the MPS sensors deliver unprecedented reliability and accuracy. Unlike traditional sensors, the MPS sensors accurately report 0-100% LEL across 19 flammable gases and 6 refrigerant gases with a single factory calibration and no field maintenance over their lifetime. The MPS Flammable Gas sensors’ accuracy is enhanced by integrated, real-time measurements and built-in compensation for temperature, pressure, and humidity. Gas concentration readings are accurate across the full environmental range including rapid environmental transients, delivering best-in-class false-positive accuracy. The company’s MPS sensors are inherently immune to drift, decay, or poison.
For more information contact NevadaNano at info@nevadanano.com
About NevadaNano
NevadaNano's programmable, multi-gas detection technology is the first new approach to flammable gas detection in over 40 years. The MPS technology was developed with the support of DARPA, the DOD, and the Department of Homeland Security for the most challenging gas detection applications and is the winner of the coveted R&D100 award and the Tech Connect National Innovation award. The sensors utilize 24 patented inventions to tackle the toughest chemical analysis tasks. For information visit NevadaNano.com or connect on LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210518005868/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom